Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

Coronary Artery Disease Clinical Trial

Official title:

A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02086045
• Other study ID #: ELX-CL-1003
• Status: Completed
• Phase: N/A
• Start date: November 2011
• Est. completion date: May 15, 2017

Study information

• Verified date: September 2023
• Source: Elixir Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety, performance and efficacy of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native coronary artery lesion designated the target lesion and up to one non-target lesion located in a separate epicardial vessel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 126
• Est. completion date: May 15, 2017
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient must be at least 18 years of age and for the 35-patient subset, patients must be over the age of 50

• Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the DESolve Nx Novolimus Eluting BCSS and he/she provides written informed consent, as approved by the appropriate Ethics Committee of the respective clinical site, prior to any clinical study related procedure

• Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)

• Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery

• Patient must agree to undergo all clinical study required follow-up visits, angiograms, and as applicable, IVUS, OCT, MSCT and coronary vasomotion testing

• Patient must agree not to participate in any other clinical study for a period of two years following the index procedure

Angiographic Inclusion Criteria:

Target lesion must be located in a native coronary artery with a nominal vessel diameter of between 2.75 and 3.5 mm assessed by online QCA

• Target lesion must measure = 14 mm in length

• Target lesion must be in a major artery or branch with a visually estimated stenosis of = 50% and < 90% with a TIMI flow of = 1

• Percutaneous intervention of lesions in the target vessel if:

1. Not part of a clinical investigation

2. = 6 months prior to the study index procedure

3. = 9 months after the study index procedure (planned)

4. Previous intervention was distal to and >10mm from the target lesion

Exclusion Criteria:

• Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure and CK and CK-MB have not returned within normal limits at the time of procedure

• Patient is currently experiencing clinical symptoms consistent with AMI

• Patient requires the use of any rotablator intervention during the index procedure

• Patient has current unstable arrhythmias

• Patient has a known left ventricular ejection fraction (LVEF) < 30%

• Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant

• Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure

• Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)

• Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.

• Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated

• Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel

• Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease.

• Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, or patient on dialysis)

• Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions

• Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months

• Patient has had a significant GI or urinary bleed within the past six months

• Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion

• Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)

• Patient is already participating in another clinical study

• Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing

• Patient is unable to give their consent, is legally incompetent, or is institutionalized by virtue of an order issued by the courts or other authority

Angiographic Exclusion Criteria

• Target lesion(s) meets any of the following criteria:

1. Aorto-ostial location

2. Left main location

3. Located within 5 mm of the origin of the LAD or LCX

4. Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft

5. Lesion involving a side branch >2mm in diameter or bifurcation

6. Previous placement of a scaffold proximal to or within 10 mm of the target lesion

7. Total occlusion (TIMI flow 0), or TIMI flow < 1

8. Excessive tortuosity proximal to or within the lesion

9. Angulation (= 45o) proximal to or within the lesion

10. Calcification moderate or heavy

11. Previous intervention restenosis

• The target vessel contains visible thrombus

• Another clinically significant lesion (>40%) is located in the same major epicardial vessel as the target lesion

• Patient has a high probability that a procedure other than pre-dilatation and scaffolding and (if necessary) post-dilatation will be required at the time of index procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or brachytherapy)

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
percutaneous coronary

Locations

Country	Name	City	State
Belgium	AZ Middelheim Hospital	Antwerp
Belgium	St. - Jan Ziekenhuis Z.O.L.	Genk
Brazil	Instituto Dante Pazzanese	Sao Paulo
Brazil	ICT / Instituto Do Coracao Do Triangulo Mineiro	Uberlandia
Denmark	Aarhus University Hospital, Skejby	Aarhus N
Germany	Charite - Campus Benjamin Franklin	Berlin
Germany	Universitäres Herz- und Gefäßzentrum	Hamburg
New Zealand	Auckland City Hospital	Auckland
New Zealand	Mercy Angiography Unit	Auckland
New Zealand	North Shore Hospital	Auckland
Poland	Polsko-Amerykanskie Kliniki Serca	Dabrowa Górnicza
Poland	Centrum Interwencyjnego Leczenia Chorób Serca	Krakow
Poland	Jagiellonian University	Krakow

Sponsors (1)

Lead Sponsor	Collaborator
Elixir Medical Corporation

Countries where clinical trial is conducted

Belgium,  Brazil,  Denmark,  Germany,  New Zealand,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Acute success - Procedure success	Acute Success is classified according to the following definitions: Procedure success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of < 50% by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of ischemia driven major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days post index procedure.	7 days
Other	Acute success - Device success	Acute Success is classified according to the following definitions: Device success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis < 50% by QCA (by visual estimation if QCA is unavailable). Standard pre-dilation catheters and post-dilatation catheters (if applicable) may be used. Bailout subjects will be included as device success only if the above criteria for clinical device success are met.	7 days
Primary	Clinically-indicated major adverse cardiac events (MACE)	cardiac death, target vessel MI, clinically indicated TLR	6 months
Primary	Late Lumen Loss	MLD post procedure - MLD at follow-up	6 month
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	1 month
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	12 months
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	24 months
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	3 years
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	4 years
Secondary	Major Adverse Cardiac Events	cardiac death, target vessel MI, clinically indicated TLR	5 months
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	1 month
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	6 months
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	1 year
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	2 years
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	3 years
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	4 years
Secondary	Clinically-Indicated Target Lesion Failure (TLF)	cardiac death, MI, clinically indicated TLR	5 years
Secondary	Clinically-Indicated Target Vessel Failure (TVF)	cardiac death, MI, clinically indicated TVR	1 year
Secondary	Clinically-Indicated Target Vessel Failure (TVF)	cardiac death, MI, clinically indicated TLR	2 years
Secondary	Clinically-Indicated Target Vessel Failure (TVF)	cardiac death, MI, clinically indicated TLR	3 years
Secondary	Clinically-Indicated Target Vessel Failure (TVF)	cardiac death, MI, clinically indicated TLR	4 years
Secondary	Clinically-Indicated Target Vessel Failure (TVF)	cardiac death, MI, clinically indicated TLR	5 years
Secondary	Scaffold Thrombosis	ARC defined	through 5 years